Chesterbrook, PA, United States of America

Philip Michael Pitis

This inventor holds 56 USPTO granted patents and 6 published patent applications, plus 2 CIPO patents and 12 EPO patents, primarily in Opioid Receptor Modulation (CPC class C07D). Top assignees: Janssen Pharmaceutica Nv, Trevena, Inc., Ortho Pharmaceutical Corporation. Active years: 1994-2025.

USPTO Granted Patents = 56 (Patent Applications = 6)

% Patents Active = 96.4

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 12 (Patent Applications = 20)

Average Co-Inventor Count = 5.4

ph-index = 10

Forward Citations = 479(Granted Patents)

Forward Citations (Not Self Cited) = 406(Dec 10, 2025)

Inventors with similar research interests:

Location History:

No. Wales, PA (US) (2013 - 2014)
King of Prussia, PA (US) (2019)
North Wales, PA (US) (1994 - 2024)
Chesterbrook, PA (US) (2022 - 2024)

Company Filing History:

21 out of 2,099

Janssen Pharmaceutica Nv

Ortho Pharmaceutical Corporation

patents

4. 7 out of 363

Ortho-Mcneil Pharmaceutical Corp.

patents

5. 6 out of 18

Prelude Therapeutics Incorporated

Years Active: 1994-2025

Loading Chart...

Areas of Expertise:

Opioid Receptor Ligands

Azetidinyl Diamides

Protein Arginine Methyltransferase

Delta-Opioid Receptor

Monoacylglycerol Lipase Inhibitors

S1P1 Activity Modulation

Pyrimidine Compounds

BRM Targeting Compounds

Selective Inhibitors

Heterocyclic Compounds

56 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12459950 - Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) (2025-11-04),

2. 12440506 - Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) (2025-10-14),

3. 11931350 - Opioid receptor ligands and methods of using and making same (2024-03-19),

4. 11912713 - 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same (2024-02-27),

5. 11912693 - Compounds for modulating S1P1 activity and methods of using the same (2024-02-27),

6. 11702423 - BRM targeting compounds and associated methods of use (2023-07-18),

7. 11702408 - 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same (2023-07-18),

8. 11465980 - 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same (2022-10-11),

9. 11254683 - Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) (2022-02-22),

10. 11225487 - 7-membered aza-heterocyclic containing δ-opioid receptor modulating compounds, methods of using and making the same (2022-01-18),

11. 11214574 - Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) (2022-01-04),

12. 11077098 - Opioid receptor ligands and methods of using and making same (2021-08-03),

13. 10711007 - Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) (2020-07-14),

14. 10588898 - Opioid receptor ligands and methods of using and making same (2020-03-17),

15. 10246436 - 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same (2019-04-02),

Title: Innovator Spotlight: Philip Michael Pitis

Introduction:

Philip Michael Pitis, a prolific inventor based in Chesterbrook, PA (US), has made significant contributions to the field of pharmaceuticals with 54 patents to his name. His groundbreaking work focuses on developing compounds that can act as opioid receptor ligands, revolutionizing the treatment of pain and related disorders.

Latest Patents:

Pitis' latest patents include "Opioid receptor ligands and methods of using and making same," which detail compounds essential for managing pain and pain-related conditions. Additionally, his patent on "7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds" highlights his commitment to advancing treatments for pain, migraines, depression, Parkinson's Disease, anxiety, and other disorders.

Career Highlights:

Throughout his career, Pitis has worked with esteemed pharmaceutical companies such as Janssen Pharmaceutica Nv and Trevena, Inc. His innovative approach to drug development has led to the creation of groundbreaking medications that have the potential to improve the lives of countless individuals worldwide.

Collaborations:

Pitis has collaborated closely with notable colleagues in the field, including Haiyan Bian and Li Liu, bringing together diverse expertise to drive innovation and excellence in pharmaceutical research. These collaborations have been instrumental in advancing the development of novel treatments and therapies.

Conclusion:

In conclusion, Philip Michael Pitis stands out as a visionary inventor in the pharmaceutical industry, with a portfolio of patents that reflect his dedication to improving healthcare outcomes. His pioneering work in opioid receptor ligands underscores his commitment to innovation and his significant contributions to the field.